CINV Existing and Pipeline Drugs Market Research and Demand: 2022, Emerging Development Trends, Growth Prospects and Innovative Plans by 2028

CINV Existing and Pipeline Drugs Market Outlook 2031
• The global CINV existing and pipeline drugs market was valued at US$ 1.9 Bn in 2021
• It is estimated to grow at a CAGR of 5.8% from 2022 to 2031
• The global CINV existing and pipeline drugs market is expected to surpass value of US$ 3.2 Bn by the end of 2031
Analysts' Viewpoint on Global CINV Existing and Pipeline Drugs Market Scenario
Large number of ongoing research & development activities, increasing healthcare investment by government, and rising geriatric population suffering from cancer are some of the factors driving the global CINV existing and pipeline drugs market. Companies in the global CINV existing and pipeline drugs market are focused on the development of novel drugs to offer better treatment to patients. However, dearth of awareness among people about the availability of effective drugs and treatments is expected to hamper the growth of the global CINV existing and pipeline drugs market during the forecast period.
Overview of Global CINV Existing and Pipeline Drugs Market
Chemotherapy-induced nausea and vomiting (CINV) refers to nausea and vomiting associated with cancer chemotherapy. CINV is one of the most common side effects experienced by cancer patients undergoing chemotherapy. Presently, several drugs are available to manage CINV; however, side effects continue to be a key concern for patients and oncologists associated with chemotherapy. Companies such as Helsinn Holding S.A., Heron Therapeutics, Inc., and Tesaro, Inc. are striving to develop new and more efficacious therapeutic solutions to treat CINV.

Request Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=776

Increase in Incidence Rate of Various Types of Cancer
The world is witnessing a continuous increase in the incidence rate of various types of cancer, which results in rise in the number of patients undergoing chemotherapy. According to estimates from the World Health Organization (WHO) in 2019, cancer is the first or second leading cause of death before the age of 70 years in 112 of 183 countries, and ranks third or fourth in a further 23 countries. These facts indicate that increase in cases of various types of cancer is likely to induce oncologists to prescribe chemotherapy to their patients for the effective treatment of cancer, thereby driving the CINV existing and pipeline drugs market.
Generally, 25% to 30% patients with cancer receive chemotherapy as a treatment option, and 70% to 80% of these patients undergoing chemotherapy exhibit nausea and vomiting as major symptoms.

Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=776

Companies Undertaking R&D Activities to Develop Advanced Drugs
Significant rise in cancer research and development efforts and increase in attention on the development of novel therapies are expected to drive the global CINV existing and pipeline drugs market over the next few years. Additionally, the introduction of new pharmaceuticals and the rapid growth of the healthcare industry are expected to propel the market in the near future. However, consumers' lack of information regarding the availability of innovative and effective pharmaceuticals and treatments is projected to impact the growth of the market in the next years.
SUSTOL (APF-530) Segment to Dominate Global Market
SUSTOL (APF-530) was launched in 2015. The approval of SUSTOL drugs is likely to drive the global market during the forecast period. Increase in the number of patients undergoing chemotherapy is expected to contribute to the growth of the global CINV existing and pipeline drugs market. Various sources indicate that 70% to 80% cancer patients on chemotherapy exhibit nausea and vomiting as major side effects.

Rolapitant to Witness Demand Due to Ability to Suppress Vomiting
Rolapitant was approved in 2015. Since then, the demand for the drug has increased among various countries. Pipeline drugs have shown better efficacy than existing drugs during the clinical study. Rolapitant is used with other drugs to delay nausea and vomiting caused by cancer drug treatment (chemotherapy). It acts by suppressing one of the body's natural chemicals (substance P/neurokinin 1) that produces vomiting. Therefore, the launch of these more efficacious drugs is likely to encourage physicians to prescribe these new drugs over existing drugs
Regional Outlook of Global CINV Existing and Pipeline Drugs Market
The global CINV existing and pipeline drugs market has been segmented into North America, Europe, Asia Pacific Latin America, and Middle East & Africa. North America was the largest market for CINV drugs in 2021, accounting for over 45% share. The region is expected to retain its leadership position during the forecast period. The market in North America is likely to expand at a CAGR of over 7% from 2022 to 2031.
Europe was the second largest market for CINV drugs in 2021. The launch of CINV pipeline drugs in Europe is projected to be a year later than in North America, given the delays on the past launches of CINV drugs such as Aloxi and Emend.
The CINV existing and pipeline drugs market in Asia Pacific is driven by increase in penetration of western companies and rise in the number of cancer patients. Generic manufacturers in countries in Asia Pacific and emerging regions compete with the branded CINV drug manufacturers. The demand for generic versions of expired branded drugs is high in the region due to low purchasing power of the people. Strong economic growth in countries such as India and China and improving healthcare infrastructure are anticipated to drive the CINV existing and pipeline drugs market in Asia Pacific.

Request Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=776

Analysis of Key Players in Global CINV Existing and Pipeline Drugs Market
Key players operating in the global CINV existing and pipeline drugs market include GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc., and Tesaro, Inc. Each of these players has been profiled in the global CINV existing and pipeline drugs market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments.

Request for covid19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=776

Trending Reports:

https://www.transparencymarketresearch.com/flavours-into-overthecounter-otc-pharmaceuticals-market.html

https://www.transparencymarketresearch.com/secondary-progressive-multiple-sclerosis-treatment-market.html

Contact
Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/

About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

This release was published on openPR.